Provided by Tiger Fintech (Singapore) Pte. Ltd.

Legend Biotech

28.43
-0.8900-3.04%
Volume:1.95M
Turnover:55.87M
Market Cap:5.24B
PE:-23.89
High:29.61
Open:29.50
Low:28.16
Close:29.32
Loading ...

Legend Biotech Reveals 5-Year Survival Data for CARVYKTI® at ASCO 2025

TIPRANKS
·
Yesterday

Legend Biotech unveils five-year survival data fro CARVYKTI

TIPRANKS
·
Yesterday

Legend Biotech Announces Promising Phase 1 Results for LB2102 CAR-T Therapy in Lung Cancer Patients

Reuters
·
Yesterday

Buy Rating for Legend Biotech Driven by Carvykti’s Market Position and Efficacy

TIPRANKS
·
02 Jun

Legend Biotech’s Carvykti Shows Strong Potential and Undervalued Stock Presents Attractive Investment Opportunity

TIPRANKS
·
02 Jun

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT)

TIPRANKS
·
27 May

Exploring High Growth Tech Stocks In The US This May 2025

Simply Wall St.
·
23 May

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Merus (MRUS) and Exelixis (EXEL)

TIPRANKS
·
23 May

Legend Biotech to Present New CARVYKTI Data at 2025 ASCO and EHA Meetings

TIPRANKS
·
23 May

Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings

Reuters
·
23 May

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

GlobeNewswire
·
23 May

Stock Track | Legend Biotech Soars 5% as Investors Anticipate Key Updates at ASCO Meeting

Stock Track
·
20 May

Stock Track | Legend Biotech Soars 5% as Company Announces Investor Event at ASCO Annual Meeting

Stock Track
·
20 May

Legend Biotech Corporation to Host Investor Event During American Society of Clinical Oncology Annual Meeting

Reuters
·
19 May

Legend Biotech Shares Have 'Meaningful Upside' With Continued Execution, RBC Says

MT Newswires Live
·
16 May

Legend Biotech’s Promising Outlook: Strong Demand, Capacity Expansion, and Market Leadership Drive Buy Rating

TIPRANKS
·
16 May

Stock Track | Legend Biotech Plummets 5% as Analysts Cut Price Targets Following Q1 Results

Stock Track
·
16 May

Stock Track | Legend Biotech Plummets 5.19% Despite Narrower Q1 Loss and Strong CARVYKTI® Sales

Stock Track
·
16 May

BUZZ-U.S. STOCKS ON THE MOVE-Robinhood, Oklo, Chimera Investment

Reuters
·
15 May

Legend Biotech Is Maintained at Buy by Truist Securities

Dow Jones
·
15 May